Prolonged Post-Electroconvulsive Therapy Delirium Controlled With Donepezil

Prolonged post-ECT delirium associated With substance-induced psychosis: A case report

Electroconvulsive therapy (ECT) is an effective treatment for various psychiatric conditions. Although rare, prolonged post-ECT delirium is a serious adverse effect of ECT. Various factors, such as underlying brain pathologies, medications, seizure duration, and type of electrode placements play a role in the development of post-ECT delirium. We report a 56-year-old male suffering from 14-day-long post-ECT delirium associated with substance misuse, pesticide exposure, as well as ischemic brain changes. On the basis of the insights from this case, it may be suggested that all patients should be screened for risk factors associated with ECT-related delirium before ECT and that various parameters, such as electrode placement and medications, should be adjusted accordingly.

The Role of Acetylcholinesterase Inhibitors in the Treatment of Prolonged Postelectroconvulsive Therapy Delirium

Electroconvulsive therapy (ECT) is an extremely effective treatment modality for severe depression but is often associated with transient or persistent cognitive impairment. ECT-induced cognitive impairment, however, can serve as a deterrent to completion of treatment. We present a case of a prolonged post-ECT delirium lasting approximately 3 weeks in which donepezil, an acetylcholinesterase inhibitor, was used and was successful in shortening the duration of post-ECT delirium.

The Efficacy and Safety of Concomitant Psychotropic Medication and Electroconvulsive Therapy (ECT)

Electroconvulsive therapy (ECT) is an effective treatment for severe psychiatric disorders. Patients referred to ECT are often taking multiple medications, many of which can potentially affect the safety and efficacy of their course of ECT. This review evaluates the impact of a variety of psychotropic medications often used in conjunction with ECT and examines strategies to optimize their management. The review encompasses mood stabilizers, antidepressants, benzodiazepines, antiepileptics, antipsychotics, and other commonly used psychotropics.